MAXCYTE, INC.
Close on Oct 19, 2026
- Market cap
- $138.87M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | $7.30M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | $9.70M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | After market close | $6.80M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | $8.50M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | $10.40M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 12, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| total cash, cash equivalents and investments | 2026 | $130.50M | Lowered |
| Full year revenue | Full Year 2026 | $30.00M to $32.00M | Maintained |
| Core revenue | Full Year 2026 | $25.00M to $27.00M | Lowered |
| SPL Program-related revenue | Full Year 2026 | $5.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Maxcyte filed with the SEC
MaxCyte Reports Preliminary Third Quarter 2026
Results of operations · EX-99.1 to Form 8-K
MaxCyte Reports Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
are trademarks of MaxCyte, Inc. in the U.S.A.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
are trademarks of MaxCyte, Inc. in the U.S.A.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
are trademarks of MaxCyte, Inc. in the U.S.A.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
are registered trademarks of MaxCyte, Inc. in the U.S.A.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
are registered trademarks of MaxCyte, Inc. in the U.S.A.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
TM is a trademark of MaxCyte, Inc.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
TM is a trademark of MaxCyte, Inc.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target
Regulation FD disclosure · EX-99.1 to Form 8-K
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
MaxCyte Announces Retirement of Board Member Art Mandell
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
TM is a trademark of MaxCyte, Inc.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MaxCyte Appoints Cynthia Collins to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
TM is a trademark of MaxCyte, Inc.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
TM is a trademark of MaxCyte, Inc.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
Results of operations · EX-99.1 to Form 8-K
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
Results of operations · EX-99.1 to Form 8-K
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
Results of operations · EX-99.1 to Form 8-K
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
Results of operations · EX-99.1 to Form 8-K